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ABSTRACT
Lymphatic filariasis (LF) is endemic in 81 countries in the world, and a number of these countries have targeted
for LF elimination. This review of literature and analysis was conducted to identify additional and sustainable
strategies to accelerate LF elimination from endemic countries. This review noted that adverse events due to
mass drug administration (MDA) of diethyl carbamazine (DEC) tablets, poor knowledge and information about
LF amongst health workers & community members, and limited focus on information, education & communication
(IEC) activities and interpersonal communication are the major barriers in LF elimination. The new approaches
to increase compliance with DEC tablets (including exploring the possibility for DEC fortification of salt),
targeted education programmes for physicians and health workers, and IEC material and inter personal
communication to improve the knowledge of community are immediately required. There is a renewed and
pressing need to conduct operational research, evolve sustainable and institutional mechanisms for education of
physicians and health workers, ensure quality of trainings on MDA, strengthen IEC delivery mechanisms,
implement internal and external monitoring of MDA activities, sufficient funding in timely manner, and to
improve political and programmatic leadership. It is also time that lessons from other elimination programmes
are utilized to accelerate targeted LF elimination from the endemic countries.
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Background
Lymphatic filariasis (LF) is endemic in 81 countries
of the world and is the second leading cause of permanent
disability and meets the criteria for being a potentially
eradicable disease1–3. The World Health Organization
(WHO) estimates that 1.1 billion people live in high risk
areas, 120 million of these people are already infected with
LF, and 76 million people have suffered from damaged
lymphatic and renal systems3,4. Southeast Asia Region con-
tributes to almost 2/3rd of global cases with India having a
total of 590 million people at risk of LF, and 10% of them
already suffering from LF5. Mass drug administration
(MDA) with diethyl carbamazine (DEC) tablets has been
proven as the most feasible strategy for LF elimination
(recently, a few countries have started using DEC and
albendazole tablets in MDA)6,7. MDA has been imple-
mented in 51 of the 71 eligible countries4. It is recom-
mended that a coverage rate of 70 to 80% continuously
for 5–6 yr be achieved during the annual MDA campaign
to reduce transmission at very low level3,4. However, MDA
activities have achieved limited success, even after rec-
ommended coverage is achieved. The most common rea-
son cited for partial success in MDA has been the poor
compliance with DEC tablet consumption, due to adverse
drug reactions8,9. Therefore, search for additional and syn-
ergistic approaches to achieve LF elimination is an urgent
felt need10,11. This review analyzes the bottlenecks in
achieving high coverage with MDA, and identifies sus-
tainable additional strategies to guide the world towards
accelerated LF elimination.
Data synthesis
The published information was collected from major
bibliographic databases for biomedical journals, i.e.
PubMed, EMBASE, Scopus, Google Scholar, Ovid, &
WHO Database. Hand search of the articles and full text
of the cross references on lymphatic filariasis and mass
drug administration (MDA) was conducted. Personal com-
munication, either by phone or e-mails, was made with
researchers and experts on LF in India and other coun-
tries. The main focus was on community-based studies,
and findings from endemic countries. Articles on use of
health education material and inter personal communica-
tion were analyzed to assess their effectiveness to increase J Vector Borne Dis 48, March 2011 2
the compliance for MDA. This systematic search gener-
ated a number of articles, which were further shortlisted
for inclusion in the review. Full texts of all relevant ar-
ticles and the information received from experts were read
and analyzed and available evidences and main findings
were summarized. The suggestions to improve performance
are based upon the literature review and analysis and also
on the programmatic insight and carefully considered
judgement of the authors, one of whom (CL) has exten-
sively been involved in the activities related to LF elimi-
nation.
Existing challenges in LF elimination
Improve coverage and compliance with DEC
MDA has been or is being done in 51 countries for
achieving LF elimination; however, the success has been
inconsistent4. Studies have noted that in spite of high cov-
erage, compliance is poor12–16. The major reason for poor
results with MDA is the low compliance, which is desir-
able but difficult to achieve12.
A possible approach to address the issue of poor com-
pliance with MDA has been seen in salt fortification. It
was reported that salt fortification with DEC have been
significantly reduced the prevalence and density of mi-
crofilariae1,17. There is evidence from Brazil, China, Tan-
zania, India, and Japan to suggest significant reduction in
LF by way of salt fortification with DEC17–21. These stud-
ies point out that DEC fortified salt might have both mi-
cro-filaricidal and adulticidal properties with long-lasting
beneficial effects22. Furthermore, the children <2 yr of age,
and pregnant women are excluded from MDA and salt
fortification addresses these challenges23–24. Salt fortifi-
cation has shown similar results in one or two years than
what we expect at the end of 4–6 yr of MDA, with mini-
mal adverse effects10,11,25,26. Nevertheless, it is to be noted
that continuous surveillance and other interventions are
critically important with both MDA and salt fortification
strategies27–29. There are examples from countries like Fiji,
Samoa, and French Polynesia, where prevalence was ini-
tially reduced significantly27–29 but increased subsequently
when other interventions were ignored30.
Continuous medical education for physicians and health
workers
 Physicians and health workers have been reported to
have limited knowledge about MDA, while a clear under-
standing of rationale of the MDA programme and posi-
tive attitude among physicians increases the compliance31.
A study from Orissa, India reported that only 34% of the
physicians at Primary Health Centre (PHC) and 6.7% of
the private physicians believed that elimination of LF could
be possible through MDA programme. The physicians in
private sector have poor understanding of MDA than those
in government sector and a greater proportion of them did
not believe in effectiveness of MDA strategies. Many phy-
sicians still believe that 21 days treatment is needed for
LF, which they had learned in medical schools in earlier
times16.
Educational programmes have been demonstrated to
have significantly improved knowledge of the physicians
and drug distributors32, a point in favour of an orientation
during Continued Medical Education (CME) programmes.
A study in Puducherry, India found that health workers
achieved relatively higher coverage and compliance than
non-health staff working as drug distributors. It was noted
that the health workers had better knowledge, which helped
them in passing the correct information to the beneficia-
ries and improving compliance33. Two main problems re-
ported in MDA training programmes were lack of quality
assessment, and long time lag between trainings and ac-
tual field activities34, both of which can severely affect
the quality of activities. The CME efforts targeted at health
workers can help in improving the coverage and compli-
ance as some of the knowledge into the practice of the
health worker can make significant difference.
IEC material and educational programmes
Studies have reported a statistically significant non-
compliance in individuals, who were unaware of the risk
of getting LF and benefits of MDA35,36. A few other stud-
ies have noted that only 3% of local inhabitants knew about
MDA activities, and those who were aware, could per-
ceive benefits, and were more likely to comply13,34. A study
from India reported that approximately 50% of the IEC
budget was allocated to newspaper advertisements, in a
predominantly rural setting, where people had limited ac-
cess to print media34. It was found that ‘fear of adverse
reactions’, ‘lack of perceived benefits’, and ‘inconsistent
implementation of MDA programmes’ are the chief barri-
ers to achieve compliance34,37. The studies have reported
School Health Education (SHE) as a cost-effective public
health strategy to improve compliance38. A study conducted
in endemic districts of India where school teachers were
educated about MDA activities, who in turn delivered
messages to the school students noted that these children
had shared this information with their families39. Even after
5 months, the results were statistically significant, which
indicate sustainable effects of SHE40,41. The misconcep-
tions, myths and rumours of or a true adverse event fol-
lowing MDA, may create distrust amongst the commu-
nity and health professionals involved with LF elimination3 Lahariya & Tomar: Strategic and programmatic interventions in LF elimination
strategies, which is possible to be reduced by effective
community educational programme and interpersonal
communication42.
Operational challenges and solutions
The commonest problem with MDA reported  is  in-
adequately managed adverse drug reactions, which leads
to poor compliance34,42–44. This is especially important as
the adverse reactions are more frequent in people with
higher microfilariae load, who need DEC tablets most.
The reason is that adverse reactions occur due to release
of cytokines to counter the effects of filarial antigen, re-
leased from dying microfilariae derived molecule45. Salt
fortification addresses the issue of adverse drug reactions
and resulting poor compliance. Nonetheless, better man-
agement of adverse events following MDA should be em-
phasized to ensure higher compliance.
Salt fortification with DEC has few other program-
matic and operational benefits: first, the excluded groups
of pregnant women and children <2 yr of age are also
covered in salt fortification (this group is not given DEC
tablets and work as a ‘reservoir host’ of filariasis, which
may result in rapid reversion of filaria, when coverage
and compliance is poor). Second, MDA is done in the day
time, when a majority of the targeted beneficiaries (work-
ing age groups and school going children) are not avail-
able at home34, which also contribute to poor coverage
and compliance. Switching of MDA activities to the night
schedule may not be accepted by the drug distributors and
community for variety of socio-cultural and geographic
reasons. This difficulty can be overcome by DEC forti-
fied salt. Third, DEC salt fortification procedure is
simple21, almost similar to Iodine fortification16 that can
be done even at village-level, and is logistically and eco-
nomically feasible even in the rural and remotely located
areas. Simplicity of procedure and production at village-
level can significantly reduce the cost, making it a sus-
tainable public health programme, if implemented prop-
erly. Nonetheless, salt fortification has its own challenges,
similar to that faced in Iodine fortification of salt46. There-
fore, a decision on salt fortification also requires careful
deliberation and should derive lessons from Iodine fortifi-
cation programmes in the respective countries. Further-
more, though DEC and Iodine can be fortified together in
salt without affecting their efficacy and any additional ad-
verse event39,47, many legal and ethical issues are inherent
as DEC is not a routine nutrient like Iodine and there are
issues of informed consent and governmental liabilities. It
also needs approval from the government’s ethical com-
mittee to deliver drug directly to food. Salt fortification
can also lead to complacency in programme people and
may have rebound in the LF cases, if sustained attention
to other complimentary activities is not paid.
Physicians at the Primary Health Centre (PHC) level
are the primary responsible group for the implementation
of MDA and often doctors in rural areas have great influ-
ence on the community. The influence of doctors on the
community members should be used in public health
programmes as a tool to increase community acceptance.
Lack of perceived benefits of MDA15,48,49, and fear of
adverse reactions affects compliance. The IEC material
and educational programs either are not available or are
poorly planned34, and a lack of focus on educational
programmes may cause poor compliance35. IEC material
should not be limited only to the description of facts but it
should be interactive and appealing to the local commu-
nity. Folk media for example, drum beating, would be an
excellent strategy in the rural community because of their
inherent acceptance. Messages on television, radio and
newspapers work, if strategically planned and the use of
slides in local cinema halls can work as an effective strat-
egy to provide information to the poor and rich people
simultaneously50. The poor understanding of MDA strat-
egies among health professionals14,31 need to be immedi-
ately addressed by targeted CME51.
There are other areas of attention in LF elimination.
Urban areas facilitate vector transmission more often than
rural areas52. Therefore, comprehensive strategies should
be developed for urban and crowded areas to increase com-
pliance otherwise these areas will serve as a persistent
source of filarial infection. Similarly, case management is
a forgotten part and people and health systems should be
enabled for LF case management. The presence of LF in
any community is an opportunity to understand health
system performance. Accessibility of health services should
be carefully evaluated in the endemic areas as LF is a
disease of the poor. It is because of the limited accessibil-
ity to the health services, that many poor people receive
treatment for drug adverse reaction from private practi-
tioners, at out of pocket expenditure. Therefore, identifi-
cation of community members who can record and com-
municate messages to the PHCs can substantially improve
the accessibility and can reduce the treatment cost for poor
and high risk populations. There are practical experiences
of effective management of adverse events in mass cam-
paigns following measles vaccination in India and other
countries too. In the mass measles campaigns in India,
proper training of the medical officers in Adverse Events
Following Immunization (AEFI) case management, pro-
viding them treatment kits, and generating awareness,
which helped in effective AEFI case management and suc- J Vector Borne Dis 48, March 2011 4
cessfully running the campaign. The measles campaigns
were conducted as school and community-based campaigns
and adverse event management was successful in both the
settings.
The best practices on LF elimination from different
parts of the world should be incorporated in the training
programmes, because these provide ‘visible examples’ and
help motivate work-force. A survey was conducted in an
endemic area of Japan and blood films from every com-
munity member were collected, following which subjects
were administered with DEC for 12 days. They were sub-
sequently followed up to understand the relationships be-
tween the levels of microfilariae and adverse effects of
drug administration53. This study could show the relation-
ship between drug adverse reactions to the load of mi-
crofilariae. Thereafter, findings from this study were used
to generate awareness among people by extensive com-
munity education about the MDA programme and vector
control activities. This experience also suggested that
people from other similar programmes, i.e. malaria con-
trol programme can share knowledge and experiences; and
can provide technical assistance to contribute to interdis-
ciplinary competencies to improve MDA programme per-
formance53. Experiences from within and outside the coun-
try on community-based elimination programmes, i.e.
Yaws and Polio, should be shared with people involved in
LF elimination and lessons derived for improving
programme performance54,55.
The authors also suggest a few additional points, which
are not fully covered in this review. Any opportunity for
advocacy with community leaders and other stakeholders
should be optimally utilized. Vector control measures have
proven very effective in disease control56,57 and program-
matic attention should also be on selective vector control
for LF, on night clinics, and case management aspects.
The quality of trainings prior to implementation of MDA
activities should be improved. Regular evaluation of
programme performance and intensive external monitor-
ing of MDA activities are other cross cutting areas, which
need strengthening. The broad suggestions to improve
programme performance are given in Box 1.
Conclusions
The effective strategies to improve compliance with
DEC tablet ingestion (and exploring the possibility for
salt fortification with DEC), targeted continuous medical
education programmes for physicians and health work-
ers, and IEC material to improve the knowledge of the
community, need immediate re-enforcement in the endemic
areas. Additionally, there is a renewed and immediate felt
need to conduct operational research, evolve sustainable
and institutional mechanisms for physicians and health
workers education on LF elimination and MDA, strengthen
IEC delivery mechanisms, implement internal and exter-
nal monitoring of the programme implementation, ensure
quality of trainings on MDA, make sufficient funds avail-
able in timely manner, and to improve political and pro-
grammatic leadership. The lessons from other finished and
ongoing elimination programs can also be put to use for
improving LF elimination programme. The best practices
from endemic countries should be used to accelerate LF
elimination. It is time that available programmatic knowl-
edge is optimally utilized for global elimination of LF, as
soon as possible.
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Box 1: Programmatic interventions suggested for ac-
celerated LF elimination in endemic countries
 Conduct operational research on the feasibility of
salt fortification with DEC and use those lessons for
programmatic modifications
 Evolve sustainable and institutional mechanism for
continuous medical education of physicians and other
health workers about LF, disease, elimination, and
MDA activities
 Develop IEC and inter-personal communication
strategies to generate awareness amongst commu-
nity members about LF and MDA
 Ensure the quality of the trainings conducted just
prior to the MDA activities, these trainings may be
externally monitored
 Intensive monitoring of MDA activities by external
monitors and observers, with priority being assigned
to the high focus areas
 Ensure sufficient and sustainable funds available at
various levels in a timely manner
 Enhance political leadership, with regular review of
the programme performance at various levels
 Derive and share lessons from successful implemen-
tation of other disease elimination and eradication
programmes5 Lahariya & Tomar: Strategic and programmatic interventions in LF elimination
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